Item 7.01 Regulation FD Disclosure.
On June 22, 2022, Aura Biosciences, Inc. (the “Company”) issued a press release
titled “Aura Biosciences Reports Topline Data from a Retrospective Study of
Belzupacap Sarotalocan (AU-011) versus Radiotherapy Supporting the Value of a
Vision Preserving Therapy for the Treatment of Patients with Early-Stage
Choroidal Melanoma.” The Company presented the data at the 20th congress of the
International Society of Ocular Oncology on June 19, 2022. A copy of the press
release and a copy of the presentation are attached as Exhibits 99.1 and 99.2,
respectively, to this Current Report on Form 8-K and are incorporated herein by
reference.
The information furnished under this Item 7.01, including Exhibits 99.1 and
99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press Release issued by the Company, dated June 22, 2022, furnished
herewith.
99.2 Aura Biosciences, Inc. 2022 ISOO Presentation, dated June 19, 2022,
furnished herewith.
104 Cover Page Interactive Data (embedded within the Inline XBRL document)
——————————————————————————–
© Edgar Online, source Glimpses
postbrexitcompliance.com 